Global Oncology Pharmaceuticals Market (2021 to 2026) - Featuring Abbvie, Bayer and Novartis Among Others

News provided by

Oct 06, 2021, 13:45 ET

DUBLIN, Oct. 6, 2021 /PRNewswire/ -- The "Global Oncology Pharmaceuticals Market 2021-2026" report has been added to ResearchAndMarkets.com's offering.

The global market for oncology pharmaceuticals should grow from $177.4 billion in 2021 to $313.7 billion by 2026, at a compound annual growth rate (CAGR) of 12.1% for the period of 2021-2026.

This report aims to provide a comprehensive study of the global market for oncology pharmaceuticals (cancer drugs). It provides a detailed description of the different oncology pharmaceutical types (targeted therapy, immunotherapy, chemotherapy and hormone therapy) and current and historical market revenues. The markets for oncology pharmaceuticals is also segmented based on indication (lung cancer, breast cancer, multiple myeloma, prostate cancer, non-Hodgkin's lymphoma, colorectal cancer and other cancers). The market revenue for each geographic segment, North America, Europe, Asia-Pacific and RoW, has also been provided in the report.

In order to provide an in-depth understanding of the market, profiles of market participants, competitive landscape, key competitors and respective market share are also part of this report. This report includes oncology pharmaceutical pipeline analysis and a detailed discussion of key marketed products. This report outlines driving and restraining factors of the oncology pharmaceuticals market.

The Report Includes

74 tables
An overview of the global oncology pharmaceutical market
Estimation of the market size and analyses of global market trends, with data from 2020, estimates for 2021 and projections of compound annual growth rates (CAGRs) through 2026
Highlights of the current and future market potential and quantification of oncology pharmaceutical market based on region, drug type, and application
Identification of market drivers, restraints and other forces impacting the global market and evaluation of current market size and forecast
A detailed description of risk factors, pathogenesis and stages of cancer including the TNM staging system and number staging systems, and coverage of cancer metastases, treatment approaches and non-pharmaceutical approaches to cancer
Analysis of oncology pharmaceutical pipeline products with focus on promising pipeline molecules/ drugs in development, and coverage of technological advances, scientific discoveries, and new therapies
Detailed analysis of the regulatory framework and policies, and a snapshot of FDA approved drugs for indications related to oncology
Market share analysis of the key companies of the industry and coverage of their proprietary technologies, strategic alliances, and other key market strategies and a relevant patent analysis

Oncology pharmaceuticals is a significant and growing market. It is the world's largest pharmaceutical therapeutic area. There are around 500 FDA-approved drugs for indications related to oncology. It is estimated that oncology pharmaceuticals account for approximately 20% of global pharmaceutical sales. Given the massive size of the global oncology pharmaceuticals market, all major pharmaceutical companies either have presence in this market or are discovering and developing therapies for the market. This market is highly competitive, subject to technological advances and scientific discoveries and significantly affected by new therapies, product development and commercialization.

There have been tremendous advancements in the field of oncology over the last two decades, resulting in improved quality of life and survival rates. Per the American Cancer Society, the death rate from cancer in the U.S. has declined, steadily, over the past two decades. Many innovative therapies have been launched and pharmaceutical companies continue to invest significantly in oncology research to advance the cancer treatment market. The focus of cancer treatment is rapidly shifting from a traditional one-size-fits-all approach to precision medicine, tailored treatments for individual patients. The cancer treatment market is on the verge of a paradigm shift, where patients will be treated based on the genomic profile of the tumor. The tumor-agnostic approach to cancer treatment offers great potential for growth in the oncology pharmaceuticals market.

With tremendous focus on research, the oncology pharmaceutical industry has one of the most diverse portfolios and pipelines in the pharmaceutical industry. The American Cancer Society estimates that around 1.9 million new cases of cancer will be diagnosed in the U.S. in 2021. Five-year survival rates for many cancers remain below 50%. Many cancer patients do not respond to treatment (refractory) or fail to maintain a response (relapse) during the treatment. Given the continued incidence of cancer, substantial unmet need and the tremendous focus on discovering and developing new therapies and medicines for cancer treatment, the oncology pharmaceutical market is poised for significant growth over the next five years.

Key Topics Covered:

Chapter 1 Introduction

Chapter 2 Summary and Highlights

Chapter 3 Biology of Cancer

Overview
Risk Factors for Cancer
Pathogenesis of Cancer
Stages of Cancer
The TNM Staging System
Number Staging Systems
Cancer Metastases
Routes of Metastasis
Drug Resistance
Inherent Resistance
Acquired Resistance
Treatment Approaches to Cancer
Non-pharmaceutical Approaches
Surgery for Cancer
Radiotherapy for Cancer
Ablation Therapy
Pharmacological Therapies
Personalized Cancer Therapy (Precision Medicine)

Chapter 4 Market Breakdown by Drug Type

Overview
Chemotherapy
Types of Chemotherapy Pharmaceuticals
Hormone Therapy
Types of Hormone Therapy Pharmaceuticals
Targeted Therapy
Types of Targeted Therapy Pharmaceuticals
Small Molecule Targeted Agents
Monoclonal Antibodies (mAbs)
Poly Adenosine Diphosphate-Ribose Polymerase (PARP) Inhibitors
Targeted Radioligand Therapies
Immunotherapy
Types of Immunotherapy Pharmaceuticals
Immune Checkpoint Inhibitors
Immune-Modulating Small Molecule
Monoclonal Antibodies (mAbs)
Gene Therapies
Global Market for Oncology Pharmaceuticals by Drug Type
Global Market for Targeted Therapy Pharmaceuticals by Drug Type
Global Market for Immunotherapy Pharmaceuticals by Drug Type
Global Market for Chemotherapy Pharmaceuticals
Global Market for Hormone Therapy Pharmaceuticals

Chapter 5 Market Breakdown by Application

Overview
Lung Cancer
Diagnosis
Breast Cancer
Diagnosis
Multiple Myeloma
Diagnosis
Prostate Cancer
Diagnosis
Non-Hodgkin's Lymphoma
Diagnosis
Colorectal Cancer
Diagnosis
Other Cancers
Stomach Cancer
Liver Cancer
Cervical Cancer
Esophageal Cancer
Melanoma
Leukemia
Global Market for Oncology Pharmaceuticals by Cancer Type

Chapter 6 Market Breakdown by Region

Global Markets for Oncology Pharmaceuticals by Region
North America
North American Market for Oncology Pharmaceuticals by Type
Europe
European Market for Oncology Pharmaceuticals by Type
Asia-Pacific
Asia-Pacific Market for Oncology Pharmaceuticals by Type
RoW
RoW Market for Oncology Pharmaceuticals by Type

Chapter 7 Competitive Landscape

Overview
Blockbuster Oncology Pharmaceutical Brands
Blockbuster Oncology Pharmaceuticals Brand Revenue
Blockbuster Oncology Pharmaceutical Brands, by Drug Type
Blockbuster Oncology Pharmaceuticals, by Company
Key Oncology Pharmaceutical Brands
Chemotherapy
Hormone Therapy
Targeted Therapy
Small Molecule Targeted Agents
mAb Targeted Therapy
PARP Inhibitors
Targeted Radioligand Therapies
Immunotherapy
Immune-Modulating Small Molecules
mAb Immune Therapy
Immune Checkpoint Inhibitors
Gene Therapies
Global Market Shares of Leading Companies
Recent Industry Activities

Chapter 8 New Developments and Pipeline Analysis

New Developments
Novel Oncology Drug Approvals
Biosimilar Approvals
Pipeline Analysis
Selected New Drug Molecules in Late Stages of Clinical Development
Most Studied Drug Molecules

Chapter 9 Market Dynamics

Overview
Market Trends and Growth Drivers
Favorable Global Demographics and Aging Population
Greater Incidence of Obesity and Diabetes
Robust Approval of Oncology Pharmaceuticals
Advances in Biochemistry and Genomics
High Unmet Need
Premium Pricing
Collaborations and Licensing Agreements
Mergers and Acquisitions
Challenges
Loss of Exclusivity and Genericization
Lack of Oncology Professionals
High Cost of Biologic Therapies

Chapter 10 Impact of COVID-19 Pandemic

Implications on Cancer Diagnosis
Implications on Cancer Treatment
Impact on Oncology Pharmaceuticals Market

Chapter 11 Company Profiles

Abbvie Inc.
Amgen Inc.
Astellas Pharma Inc.
AstraZeneca Plc
Bayer Ag
Bristol-Myers Squib
Eli Lilly And Co.
F. Hoffmann-La Roche Ltd.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co.
Novartis Ag
Pfizer Inc.
Sanofi-Aventis
Takeda Pharmaceutical Co. Ltd.

Chapter 12 Appendix: Acronyms

For more information about this report visit https://www.researchandmarkets.com/r/h1yivr

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1904
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets